Mechanisms of autoantibody-induced monocyte tissue factor expression

Thrombosis Research

Volumn 114, Issue 5-6 SPEC. ISS., 2004, Pages 391-396

  Wolberg, Alisa S ^a   Roubey, Robert A S ^b  

^a Dept of Pathol and Lab Medicine ^*  (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Endothelial cells; Monocytes; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; ANTITHROMBOCYTIC AGENT; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; CAPTOPRIL; DILAZEP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FLUINDOSTATIN; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAPRIL; PENTOXIFYLLINE; SIMVASTATIN; THEOPHYLLINE; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANTIGEN ANTIBODY COMPLEX; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING; ENDOTHELIUM CELL; HUMAN; HYPERCOAGULABILITY; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STATISTICAL SIGNIFICANCE; THROMBOSIS;

EID: 7044254642     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.06.012     Document Type: Article

References (60)

1. Giesen P.L.A., Rauch U., Bohrmann B., Kling D., Roque M., Fallon J.T., et al. Blood-borne tissue factor: another view of thrombosis. Proc. Natl. Acad. Sci. U. S. A. 96:1999;2311-2315
2. Bogdanov V.Y., Balasubramanian V., Hathcock J., Vele O., Lieb M., Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat. Med. 9:2003;458-462
3. Bugge T.H., Xiao Q., Kombrinck K.W., Flick M.J., Holmback K., Danton M.J., et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc. Natl. Acad. Sci. U. S. A. 93:1996;6258-6263
4. Drake T.A., Ruf W., Morrissey J.H., Edgington T.S. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. J. Cell Biol. 109:1989;389-395
5. Gregory S.A., Morrissey J.H., Edgington T.S. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol. Cell. Biol. 9:1989;2752-2755
6. Sabatier F., Roux V., Anfosso F., Camoin L., Sampol J., Dignat-Geroge F. Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factor-dependent procoagulant activity. Blood. 99:2002;3962-3970
7. Lee W.H., Kim S.H., Jeong E.M., Choi Y.H., Kim D.I., Lee B.B., et al. A novel chemokine, Leukotactin-1, induces chemotaxis, pro-atherogenic cytokines, and tissue factor expression in atherosclerosis. Atherosclerosis. 161:2002;255-260
8. Arepally G.M., Mayer I.M. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood. 98:2001;1252-1254
9. Khajuria A., Houston D.S. Induction of monocyte tissue factor expression by homocysteine: a possible mechanism for thrombosis. Blood. 96:2000;966-972
10. Celi A., Pellegrini G., Lorenzet R., DeBlasi A., Ready N., Furie B.C., et al. P-selectin induces the expression of tissue factor on monocytes. Proc. Natl. Acad. Sci. U. S. A. 91:1994;8767-8771
11. Walsh J.D., Geczy C.L. Discordant expression of tissue factor antigen and procoagulant activity on human monocytes activated with LPS and low dose cycloheximide. Thromb. Haemost. 66:1991;552-558
12. Bach R.R., Moldow C.F. Mechanism of tissue factor activation on HL-60 cells. Blood. 89:1997;3270-3276
13. Wolberg A.S., Monroe D.M., Roberts H.R., Hoffman M.R. Tissue factor de-encryption: Ionophore treatment induces changes in tissue factor activity by phosphatidylserine-dependent and -independent mechanisms. Blood Coagul. Fibrinolysis. 10:1999;201-210
14. Penn M.S., Patel C.V., Cui M.-Z., DiCorleto P.E., Chisolm G.M. LDL increases inactive tissue factor on vascular smooth muscle cell surfaces. Circulation. 99:1999;1753-1759
15. Bach R., Rifkin D.B. Expression of tissue factor procoagulant activity: regulation by cytosolic calcium. Proc. Natl. Acad. Sci. U. S. A. 87:1990;6995-6999
16. Broze G.J. Jr. Tissue factor pathway inhibitor. Thromb. Haemost. 74:1995;90-93
17. Callander N.S., Rao L.V., Nordfang O., Sandset P.M., Warn-Cramer B., Rapaport S.I. Mechanisms of binding of recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. Evidence that rEPI can bind to and inhibit factor VIIa-tissue factor complexes in the absence of factor Xa. J. Biol. Chem. 267:1992;876-882
18. Jesty J., Wun T.C., Lorenz A. Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa complex by the tissue factor pathway inhibitor in the presence and absence of heparin. Biochemistry. 33:1994;12686-12694
19. Edwards R.L., Rickles F.R., Cronlund M. Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation. J. Lab. Clin. Med. 98:1981;917-928
20. Osterud B., Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb. Haemost. 49:1983;5-7
21. Weis J.R., Pitas R.E., Wilson B.D., Rodgers G.M. Oxidized low-density lipoprotein increases cultured human endothelial cell tissue factor activity and reduces protein C activation. FASEB J. 5:1991;2459-2465
22. Pradier O., Surquin M., Stordeur P., de Pauw L., Kinnaert P., Vereerstraeten P., et al. Monocyte procoagulant activity induced by in vivo administration of the OKT3 monoclonal antibody. Blood. 87:1996;3768-3774
23. Broze G.J. Jr. Tissue factor pathway inhibitor gene disruption. Blood Coagul. Fibrinolysis. 9:1998;S89-S92
24. Kleesiek K., Schmidt M., Gotting C., Schwenz B., Lange S., Muller-Berghaus G., et al. The 536C→T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis. Thromb. Haemost. 82:1999;1-5
25. Tannenbaum S.H., Finko R., Cines D.B. Antibody and immune complexes induce tissue factor production by human endothelial cells. J. Immunol. 137:1986;1532-1537
26. Rustin M.H., Bull H.A., Machin S.J., Isenberg D.A., Snaith M.L., Dowd P.M. Effects of the lupus anticoagulant in patients with systemic lupus erythematosus on endothelial cell prostacyclin release and procoagulant activity. J. Invest. Dermatol. 90:1988;744-748
27. Hasselaar P., Derksen R.H., Oosting J.D., Blokzijl L., de Groot P.G. Synergistic effect of low doses of tumor necrosis factor and sera from patients with systemic lupus erythematosus on the expression of procoagulant activity by cultured endothelial cells. Thromb. Haemost. 62:1989;654-660
28. Branch D.W., Rodgers G.M. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. J. Am. Obstet. Gynecol. 168:1993;206-210
29. Quadros N.P., Roberts-Thomson P.J., Gallus A.S. Sera from patients with systemic lupus erythematosus demonstrate enhanced IgG binding to endothelial cells pretreated with tumour necrosis factor alpha. Rheumatol. Int. 15:1995;99-105
30. de Prost D., Ollivier V., Ternisien C., Chollet-Martin S. Increased monocyte procoagulant activity independent of the lupus anticoagulant in patients with systemic lupus erythematosus. Thromb. Haemost. 64:1990;216-221
31. Schved J.F., Gris J.C., Ollivier V., Wautier J.L., Tobelem G., Caen J. Procoagulant activity of endotoxin or tumor necrosis factor activated monocytes is enhanced by IgG from patients with lupus anticoagulant. J. Am. Hematol. 41:1992;92-96
32. Kornberg A., Blank M., Kaufman S., Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J. Immunol. 153:1994;1328-1332
33. Amengual O., Atsumi T., Khamashta M.A., Hughes G.R. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb. Haemost. 79:1998;276-281
34. Reverter J.C., Tassies D., Font J., Monteagudo J., Escolar G., Ingelmo M., et al. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein S. Arterioscler. Thromb. Vasc. Biol. 16:1996;1319-1326
35. Reverter J.C., Tassies D., Font J., Khamashta M.A., Ichikawa K., Cervera R., et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum. 41:1998;1420-1427
36. Lackner K.J., von Lerberg C., Barlage S., Schmitz G. Analysis of prothrombotic effects of two human monoclonal IgG antiphospholipid antibodies of apparently similar specificity. Thromb. Haemost. 83:2000;583-588
37. Ferro D., Saliola M., Meroni P.L., Valesini G., Caroselli C., Pratico D., et al. Enhanced monocyte expression of tissue factor by oxidative stress in patients with antiphospholipid antibodies: effect of antioxidant treatment. J. Thromb. Haemost. 1:2003;523-531
38. Zhou H., Wolberg A.S., Roubey R.A.S. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood. 2004;. in press
39. Cuadrado M.J., Lopez-Pedrera C., Khamashta M.A., Camps M.T., Tinahones F., Torres A., et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum. 40:1997;834-841
40. Dobado-Berrios P.M., Lopez-Pedrera C., Velasco F., Aguirre M.A., Torres A., Cuadrado M.J. Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb. Haemost. 82:1999;1578-1582
41. Roubey R.A., Pratt C.W., Buyon J.P., Winfield J.B. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I. J. Clin. Invest. 90:1992;1100-1104
42. Wolberg A.S., Roubey R.A.S. Anti-beta-2 glycoprotein I antibodies do not increase TF activity by de-encryption. Thromb. Res. 2004;. in press
43. Cakir B., Arnett F.C., Roubey R.A.S. Autoantibodies to tissue factor pathway inhibitor in the antiphospholipid syndrome. Arthritis Rheum. 42:1999;S281-S282. [Abstr.]
44. Forastiero R.R., Martinuzzo M.E., Broze G.J. Jr. High titers of autoantibodies to tissue factor pathway inhibitor are associated with the antiphospholipid syndrome. J. Thromb. Haemost. 1:2003;718-724
45. Adams M.J., Donohoe S., Mackie I.J., Machin S.J. Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome. J. Br. Hematol. 114:2001;375-379
46. Visvanathan S., McNeil H.P. Cellular immunity to beta 2-glycoprotein-1 in patients with the antiphospholipid syndrome. J. Immunol. 162:1999;6919-6925
47. 2 T-helper cells exert opposite regulatory effects on procoagulant activity and tissue factor production by human monocytes. Blood. 86:1995;250-257
48. Deguchi H., Takeya H., Wada H., Gabazza E.C., Hayashi N., Urano H., et al. Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes. Blood. 90:1997;2345-2356
49. Deguchi H., Takeya H., Urano H., Gabazza E.C., Zhou H., Suzuki K. Adenosine regulates tissue factor expression on endothelial cells. Thromb. Res. 91:1998;57-64
50. Broussas M., Cornillet-Lefebvre P., Potron G., Nguyen P. Adenosine inhibits tissue factor expression by LPS-stimulated human monocytes: involvement of the A3 adenosine receptor. Thromb. Haemost. 88:2002;123-130
51. de Prost D. Pentoxifylline: a potential treatment for thrombosis associated with abnormal tissue factor expression by monocytes and endothelial cells. J. Cardiovasc. Pharmacol. 25:1995;S114-S118
52. Ollivier V., Ternisien C., Vu T., Hakim J., de Prost D. Pentoxifylline inhibits the expression of tissue factor mRNA in endotoxin-activated human monocytes. FEBS Lett. 322:1993;231-234
53. Soejima H., Ogawa H., Yasue H., Kaikita K., Takazoe K., Nishiyma K., et al. Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. J. Am. Coll. Cardiol. 34:1999;983-988
54. Napoleone E., De Santo A., Camera M., Tremoli E., Lorenzet R. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ. Res. 86:2000;139-143
55. Ferro D., Basili S., Alessandri C., Cara D., Violi F. Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis. 149:2000;111-116
56. Holschermann H., Hilgendorf A., Kemkes-Matthes B., Schonburg M., Bauer E.P., Tillmanns H., et al. Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients. Transplantation. 69:2000;1830-1836
57. Rosenson R.S., Tangney C.C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 279:1998;1643-1650
58. Ferrara D.E., Liu X., Espinola R.G., Meroni P.L., Abukhalaf I., Harris E.N., et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum. 48:2003;3272-3279
59. Soderstrom T., Hedner U., Arnljots B. Active site-inactivated factor VIIa prevents thrombosis without increased surgical bleeding: topical and intravenous administration in a rat model of deep arterial injury. J. Vasc. Surg. 33:2001;1072-1079
60. Golino P., Ragni M., Cirillo P., D'Andrea D., Scognamiglio A., Ravera A., et al. Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis. Circ. Res. 82:1998;39-46